• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Craig A. Bunnell, MD, MPH, MBA


  • Bunnell CA, Losk K, Kadish S, Lin N, Hirshfield-Bartek J, Cutone L, Camuso K, Golshan M, Weingart S.Measuring opportunities to improve timeliness of breast cancer care at Dana-Farber/Brigham and Women's Cancer Center.J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S5-9.
  • Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S.High performance teamwork training and systems redesign in outpatient oncology.BMJ Qual Saf. 2013 May;22(5):405-13.
  • Bunnell CA, Weingart SN, Swanson S, Mamon HJ, Shulman LN.Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center.J Oncol Pract. 2010 Nov;6(6):283-8.
  • Bunnell CA, Shulman LN.Will we be able to care for cancer patients in the future?.Oncology (Huntingt). 2010 Dec;24(14):1343-8. Review.
  • Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN.Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.Int J Clin Oncol. 2010 Aug;15(4):390-8.
  • Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, Peck R, Thomas E.Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.Clin Breast Cancer. 2008 Jun;8(3):234-41.
  • Baertschi SW, Brunner H, Bunnell CA, Cooke GG, Diseroad B, Dorman DE, Jansen PJ, Kemp CA, Maple SR, McCune KA, Speakman JL.Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations.J Pharm Sci. 2008 Feb;97(2):883-92.
  • Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M.Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.J Clin Oncol. 2007 Aug 10;25(23):3399-406.
  • Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Cure H.Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.J Clin Oncol. 2007 Aug 10;25(23):3415-20.
  • Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM,.HER2 testing in breast cancer: NCCN Task Force report and recommendations.J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.
  • Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN.Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):496-504.
  • Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS.Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.J Clin Oncol. 2005 Nov 20;23(33):8453-60.
  • Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP.Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.J Clin Oncol. 2005 Nov 20;23(33):8340-7.
  • Elkin EB, Weinstein MC, Kuntz KM, Bunnell CA, Weeks JC.Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.Breast Cancer Res Treat. 2005 Sep;93(1):25-34.
  • Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.J Clin Oncol. 2003 Aug 1;21(15):2889-95.
  • Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E.Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.Cancer. 2003 Jun 15;97(12):2972-7.
  • Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP.Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.J Clin Oncol. 2003 Jan 1;21(1):46-53.
  • Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN.Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55.
  • Partridge AH, Bunnell CA, Winer EP.Quality of life issues among women undergoing high-dose chemotherapy for breast cancer.Harrison's Principles of Internal Medicine. 2001 Winter;14:41-50.
  • Burstein HJ, Bunnell CA, Winer EP.New cytotoxic agents and schedules for advanced breast cancer.Semin Oncol. 2001 Aug;28(4):344-58.
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.J Clin Oncol. 2001 May 15;19(10):2722-30.
  • Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP.Docetaxel administered on a weekly basis for metastatic breast cancer.J Clin Oncol. 2000 Mar;18(6):1212-9.
  • Frei E, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A.The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.Bone Marrow Transplant. 1999 Nov;24(9):939-45.
  • Bunnell CA, Winer EP.Oral 5-FU analogues in the treatment of breast cancer.Oncology (Huntingt). 1998 Oct;12(10 Suppl 7):39-43.
  • Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN.A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.Cancer. 1998 Feb 1;82(3):561-6.